Associate Professor, Department of Pediatrics; Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, 1 Partizana Zheleznyaka St., Krasnoyarsk, 660022, Russia.
Professor, Head of the Department of Medical and Biological Physics; Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, 1 Partizana Zheleznyaka St., Krasnoyarsk, 660022, Russia.
Sovrem Tekhnologii Med. 2021;12(6):98-108. doi: 10.17691/stm2020.12.6.11. Epub 2020 Dec 28.
The rapidly accumulating information about the new coronavirus infection and the ambiguous results obtained by various authors necessitate further research aiming at prevention and treatment of this disease. At the moment, there is convincing evidence that the pathogen affects not only the respiratory but also the central nervous system (CNS). is to provide an insight into the molecular mechanisms underlying the damage to the CNS caused by the new coronavirus SARS-CoV-2.
By analyzing the literature, we provide evidence that the brain is targeted by this virus. SARS-CoV-2 enters the body with the help of the target proteins: angiotensin-converting enzyme 2 (ACE2) and associated serine protease TMPRSS2 of the nasal epithelium. Brain damage develops before the onset of pulmonary symptoms. The virus spreads through the brain tissue into the piriform cortex, basal ganglia, midbrain, and hypothalamus. Later, the substantia nigra of the midbrain, amygdala, hippocampus, and cerebellum become affected. Massive death of neurons, astrogliosis and activation of microglia develop at the next stage of the disease. By day 4, an excessive production of proinflammatory cytokines in the brain, local neuroinflammation, breakdown of the blood-brain barrier, and impaired neuroplasticity are detected. These changes imply the involvement of a vascular component driven by excessive activity of matrix metalloproteinases, mediated by CD147. The main players in the pathogenesis of COVID-19 in the brain are products of angiotensin II (AT II) metabolism, largely angiotensin 1-7 (AT 1-7) and angiotensin IV (AT IV). There are conflicting data regarding their role in damage to the CNS in various diseases, including the coronavirus infection.The second participant in the pathogenesis of brain damage in COVID-19 is CD147 - the inducer of extracellular matrix metalloproteinases. This molecule is expressed on the endothelial cells of cerebral microvessels, as well as on leukocytes present in the brain during neuroinflammation. The CD147 molecule plays a significant role in maintaining the structural and functional integrity of the blood-brain barrier by controlling the basal membrane permeability and by mediating the astrocyte-endothelial interactions. Via the above mechanisms, an exposure to SARS-CoV-2 leads to direct damage to the neurovascular unit of the brain.
深入了解新型冠状病毒 SARS-CoV-2 对中枢神经系统(CNS)损伤的分子机制。
通过分析文献,提供病毒靶向大脑的证据。SARS-CoV-2 借助鼻腔上皮的靶蛋白血管紧张素转换酶 2(ACE2)和相关丝氨酸蛋白酶 TMPRSS2 进入人体。在出现肺部症状之前,大脑就已出现损伤。病毒通过脑组织扩散到梨状皮层、基底神经节、中脑和下丘脑。随后,中脑的黑质、杏仁核、海马体和小脑也会受到影响。在下一阶段疾病中,神经元大量死亡、星形胶质细胞增生和小胶质细胞激活。到第 4 天,大脑中促炎细胞因子过度产生、局部神经炎症、血脑屏障破坏和神经可塑性受损。这些变化表明,基质金属蛋白酶过度活跃驱动的血管成分参与其中,由 CD147 介导。COVID-19 在大脑中的发病机制中的主要参与者是血管紧张素 II(AT II)代谢产物,主要是血管紧张素 1-7(AT 1-7)和血管紧张素 IV(AT IV)。在包括冠状病毒感染在内的各种疾病中,它们对中枢神经系统损伤的作用存在相互矛盾的数据。导致 COVID-19 大脑损伤的第二个参与者是 CD147-细胞外基质金属蛋白酶的诱导剂。该分子在大脑微血管内皮细胞上表达,也在神经炎症时存在于大脑中的白细胞上。CD147 分子通过控制基底膜通透性和介导星形胶质细胞-内皮细胞相互作用,在维持血脑屏障的结构和功能完整性方面发挥重要作用。通过上述机制,SARS-CoV-2 的暴露会直接导致大脑神经血管单元的损伤。